HIGH-VOLUME · SEX-BALANCED
semaglutide Side Effects
semaglutide (also sold as Ozempic, Wegovy) is HIGH-VOLUME in this FAERS book #102 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 67% of sex-coded reports are female (43,872 F / 21,741 M).
Data updated 2026-05-15
- 72,117
- FAERS reports
FAERS voluntary reports, 2013 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
semaglutide reporting skew - 67% of sex-coded reports are female (43,872 F / 21,741 M). Volume band HIGH-VOLUME #102 of 524 by FAERS report count; caseload CASELOAD.
High-report extract for semaglutide (Ozempic): 72,117 FAERS rows (2013-2025). Top named reactions: NAUSEA, VOMITING, DIARRHOEA. Outcome stamps DEATH-MARKED · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2013–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
NAUSEA leads 10,666 of 72,117 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (17,703 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 1,213 reports (1.7% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 384 |
| NAUSEA | 84 |
| LACTIC ACIDOSIS | 75 |
| VOMITING | 68 |
| CARDIAC ARREST | 63 |
| DIARRHOEA | 54 |
| MYOCARDIAL INFARCTION | 52 |
| ACUTE KIDNEY INJURY | 48 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 46 |
| COMPLETED SUICIDE | 45 |
| PANCREATIC CARCINOMA | 42 |
| WEIGHT DECREASED | 42 |
| RENAL FAILURE | 40 |
| DECREASED APPETITE | 39 |
| ABDOMINAL PAIN | 36 |
| DEHYDRATION | 32 |
| SEPTIC SHOCK | 32 |
| DYSPNOEA | 31 |
Reactions in Hospitalization Reports
Hospitalization mid-share (14,700, 20.4%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| NAUSEA | 2,470 |
| VOMITING | 2,446 |
| DIARRHOEA | 1,753 |
| IMPAIRED GASTRIC EMPTYING | 1,585 |
| DEHYDRATION | 1,249 |
| CONSTIPATION | 1,101 |
| DECREASED APPETITE | 1,051 |
| ABDOMINAL PAIN | 973 |
| INTESTINAL OBSTRUCTION | 686 |
| ABDOMINAL PAIN UPPER | 682 |
| WEIGHT DECREASED | 663 |
| PANCREATITIS | 618 |
| ACUTE KIDNEY INJURY | 612 |
| FATIGUE | 602 |
| FALL | 596 |
| DIZZINESS | 570 |
| ASTHENIA | 537 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 529 |
| HEADACHE | 509 |
How to read semaglutide FAERS figures (CASELOAD · DEATH-MARKED · HOSP-MID)
FAERS holds 72,117 voluntary reports linked to semaglutide (Ozempic, Wegovy, Rybelsus), 2013-2025. Death is listed on 1,213 (1.7%). Hospitalization appears on 14,700 (20.4%). Top co-reported indication: Product Used For Unknown Indication.
CASELOAD books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.
Read with semaglutide
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 72,146 FAERS cases (Δ 29 heavier vs semaglutide); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 71,900 FAERS cases (Δ 217 lighter vs semaglutide); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 72,729 FAERS cases (Δ 612 heavier vs semaglutide); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 72,798 FAERS cases (Δ 681 heavier vs semaglutide); DEATH-MARKED · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 60.4 pp vs semaglutide's DEATH-MARKED): CASELOAD · HOSP-MID.
semaglutide sits in CASELOAD; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.